Beckman Coulter

AHEAD Medicine Corporation Reveals Cross-Test AML Diagnostic Technique at ASH 2023

Retrieved on: 
Thursday, January 11, 2024
SAN, Beckman Coulter, Classification, ASH, Poster, Acute myeloid leukemia, Conference, Research, Flow cytometry, Society

SAN JOSE, Calif., Jan. 11, 2024 /PRNewswire/ -- AI HealthTech startup AHEAD Medicine Corporation is delighted to announce its poster presentation at the esteemed American Society of Hematology (ASH) 2023 Conference.

Key Points: 
  • SAN JOSE, Calif., Jan. 11, 2024 /PRNewswire/ -- AI HealthTech startup AHEAD Medicine Corporation is delighted to announce its poster presentation at the esteemed American Society of Hematology (ASH) 2023 Conference.
  • The study presented at ASH 2023 focused on the integration of diagnostic data measured using both BD Biosciences and Beckman Coulter panels.
  • AHEAD Medicine's dedication to enhancing healthcare access through innovative data analysis in healthcare is reflective of its ongoing mission to devise solutions that navigate the intricacies of contemporary medicine.
  • For further details about AHEAD Medicine and to view the poster at ASH 2023, please visit https://www.aheadmedicine.com/publications/2023ash

Rare Element Resources Announces Plans for Management Change

Retrieved on: 
Friday, January 5, 2024
Mining, Minerals, Natural Resources, General Atomics, National Environmental Policy Act, Electronics, Beckman Coulter

Rare Element Resources Ltd. (the “Company” or “RER”) (OTCQB: REEMF) announces that its President and Chief Executive Officer Brent Berg, has notified the Company that he will resign his position effective April 2, 2024, or earlier at the discretion of the RER Board of Directors (the “Board”).

Key Points: 
  • Rare Element Resources Ltd. (the “Company” or “RER”) (OTCQB: REEMF) announces that its President and Chief Executive Officer Brent Berg, has notified the Company that he will resign his position effective April 2, 2024, or earlier at the discretion of the RER Board of Directors (the “Board”).
  • Mr. Berg, who has held that position since November 1, 2022, advised the Company that he will be moving to a new opportunity outside of the rare earth industry.
  • Rare Element Resources Ltd. is a publicly traded, strategic materials company focused on delivering rare earth products for technology, energy, and defense applications by advancing the Bear Lodge Rare Earth Project in northeast Wyoming.
  • Rare Element Resources’ majority shareholder, Synchron, is an affiliate of General Atomics.

Rare Element Resources Receives DOE Approval to Proceed with Construction of Rare Earth Processing and Separation Demonstration Plant

Retrieved on: 
Thursday, December 21, 2023
Building Systems, Natural Resources, Other Construction & Property, Construction & Property, Mining, Minerals, General Atomics, Demonstration plant, RER, National Environmental Policy Act, Electronics, Energy efficiency, DOE, Beckman Coulter, Rare-earth element

This approval, along with the DOE’s recent completion of its National Environmental Policy Act review, allows commencement of construction of the Demonstration Plant, located in Upton, Wyoming.

Key Points: 
  • This approval, along with the DOE’s recent completion of its National Environmental Policy Act review, allows commencement of construction of the Demonstration Plant, located in Upton, Wyoming.
  • The Company expects plant operations to commence in the third quarter of 2024, following the seven-to-10-month construction period.
  • The Demonstration Plant is expected to advance the Company’s proprietary processing and separation technology and generate the operational and economic data necessary for design of a commercial-scale plant.
  • Rare Element Resources Ltd. is a publicly traded, strategic materials company focused on delivering rare earth products for technology, energy, and defense applications by advancing the Bear Lodge Rare Earth Project in northeast Wyoming.

Synchron Appoints Andy Rasdal to Board of Directors

Retrieved on: 
Monday, December 11, 2023
Other Health, Other Science, Research, Software, Finance, Medical Devices, Hardware, Hospitals, Professional Services, Data Management, Science, Technology, Clinical Trials, FDA, General Health, Neurology, Surgery, Health, Health Technology, San Jose State University, Master of Management, BCI, Boston Scientific, Medtronic, ACS, DXCM, CGM, AVE, Patient, Multimedia, Global marketing, Master, Obesity, Dexcom, Guidant, Paralysis, Disability studies, IPO, Cardiovascular System Dynamics Society, Management, Seizure, EEG, Diabetes, Police, Pharmaceutical industry, Beckman Coulter

Synchron , the endovascular brain-computer interface (BCI) company developing technology designed to restore functionality in patients with motor impairment, today announced the appointment of Andy Rasdal to its Board of Directors.

Key Points: 
  • Synchron , the endovascular brain-computer interface (BCI) company developing technology designed to restore functionality in patients with motor impairment, today announced the appointment of Andy Rasdal to its Board of Directors.
  • “Andy joining the Board is a windfall for Synchron.
  • “His career exposure to over 15 PMAs, in particular, leading DexCom through FDA approval and an eventual IPO, will be invaluable to Synchron.”
    “I’m excited to join the Synchron Board of Directors.
  • Synchron has a broad technology platform with the potential to become the market-leading implantable neurotechnology company.”
    Before DexCom, Mr. Rasdal was President, Medtronic Vascular.

Rare Element Resources Announces Receipt of Final NEPA Approval for Rare Earth Processing and Separation Demonstration Plant

Retrieved on: 
Thursday, November 16, 2023
Other Energy, Mining, Minerals, Manufacturing, Alternative Energy, Natural Resources, Energy, Other Manufacturing, Demonstration plant, Joe Biden, Department of Defence, General Atomics, Primary energy, Risk, Electronics, RER, Bear, Energy efficiency, The Open House, National Environmental Policy Act, Beckman Coulter, Open House, DOE, NEPA, Corrosion, Bear Lodge Mountains, Rare-earth element

The DOE NEPA review was consistent with the U.S. Nuclear Regulatory Commission’s NEPA review, with both resulting in a finding of no significant impact.

Key Points: 
  • The DOE NEPA review was consistent with the U.S. Nuclear Regulatory Commission’s NEPA review, with both resulting in a finding of no significant impact.
  • The Company is awaiting next stage budget approval from the DOE, which is providing approximately 50% of the project costs, to commence construction.
  • The Demonstration Plant will advance the Company’s proprietary recovery and separation technology, and the operational and economic data generated will be essential to the design of a commercial-scale plant.
  • Rare Element Resources Ltd. is a publicly traded, strategic materials company focused on delivering rare earth products for technology, energy, and defense applications by advancing the Bear Lodge Rare Earth Project in northeast Wyoming.

MeMed Further Solidifies Board of Directors Appointing Scott Garrett

Retrieved on: 
Thursday, November 9, 2023
Water, MA, AdvaMed, Dade Behring, Health, Senior, Internet meme, Growth, Baxter International, Water Street, Minerva Surgical, Inc. v. Hologic, Inc., Beckman Coulter, Management

HAIFA, Israel; BOSTON, MA – 9 November, 2023 – MeMed, a leader in host response technologies, today announces the appointment of Scott Garrett to its Board of Directors.

Key Points: 
  • HAIFA, Israel; BOSTON, MA – 9 November, 2023 – MeMed, a leader in host response technologies, today announces the appointment of Scott Garrett to its Board of Directors.
  • Scott Garrett is currently a Senior Operating Partner at Water Street Healthcare Partners, a private equity firm focused solely on healthcare investments.
  • I'm truly enthusiastic about my appointment to MeMed's Board of Directors and eagerly anticipate helping the MeMed team achieve its operational and strategic goals.”
    Dr. Eran Eden, CEO of MeMed, noted, “We’re excited to welcome Scott Garrett to our Board and leadership team.
  • I look forward to working with Scott to further our mission and establish MeMed as a leader in the emerging field of advanced host-response.”

Pillar Biosciences to Present New Scientific Data at Association for Molecular Pathology Annual Meeting

Retrieved on: 
Wednesday, November 8, 2023
Pillar, Laboratory, NSCLC, Liquid biopsy, AMP, IVD, Bandwidth (signal processing), Microsatellite instability, Automation, MSI, Neoplasm, Research, Microdissection, AM, Beckman Coulter, Detection, Chemistry, Test management, UMI, RUO, Methylation, NGS, Targeted molecular therapy for neuroblastoma, CRC, Health care, Partnership, HRD, Urinary cell-free DNA, Column, Pension fund, Medical imaging, Instrumentation, Multiplexing

NATICK, Mass., Nov. 8, 2023 /PRNewswire/ -- Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced the company and scientific collaborators will collectively present eleven studies and two corporate workshops at the 2023 Association for Molecular Pathology (AMP) Annual Meeting from November 14 -18, 2023 in Salt Lake City, UT (Booth #619).

Key Points: 
  • NATICK, Mass., Nov. 8, 2023 /PRNewswire/ -- Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced the company and scientific collaborators will collectively present eleven studies and two corporate workshops at the 2023 Association for Molecular Pathology (AMP) Annual Meeting from November 14 -18, 2023 in Salt Lake City, UT (Booth #619).
  • "Pillar Biosciences is committed to developing the data necessary to support the quality, accuracy and value of our leading IVD & RUO kitted products which can be used locally by laboratories to perform NGS sequencing," said Randy Pritchard, CEO of Pillar Biosciences, Inc. "We are proud to present these data in partnership with our collaborators at this year's AMP Annual Meeting as we continue to enable more laboratories globally with NGS assays that can be performed in a low-cost, high-multiplexed manner, thus enabling actionable, accessible NGS profiling results."
  • The scientific data presented at AMP will focus on Pillar Biosciences oncoReveal™ Research-Use-Only (RUO) kitted NGS products for liquid biopsy (LBx), HRD, methylation, solid tumor and automation.
  • Localized NGS-based Methylation Testing to Help Inform BioPharma Clinical Trials and Improve Patient Care in Oncology (Room 251F: 8:00-8:50 AM MDT)
    Highly Accurate and Automated NGS assays for Efficient Localized LBx and TBx Clinical Testing in Oncology (Room 251F: 9:00-9:51 AM MDT)
    Comparative Laboratory Performance Evaluation of Pillar Biosciences, ArcherDx, and ThermoFisher Sequencing Chemistries for The Targeted Characterization of CRC & NSCLC Samples (Poster Number: ST120)
    Robust Low Frequency Somatic Variant Detection in cfDNA Using a SLIMamp® Based Liquid Biopsy Assay (Poster Number: ST035)
    Detection of Microsatellite Instability (MSI) Using oncoReveal Core LBx, a Multiplexed, Single Tube, Liquid Biopsy Assay (Poster Number: ST107)
    Automation of The Pillar Biosciences oncoReveal Solid Tumor 22 gene panel (ORST22) on the Biomek NGeniuS Next Generation Library Prep System (Poster Number: ST029)
    QCPRECISE!™: An Automated Spatially Targeted Microdissection Platform Driven by AI Guided Digital Pathology Improves Extracted Solid Tumor DNA Purity Relative to Conventional Macrodissection (Poster Number: TT007)
    To UMI or Not to UMI: Obtaining Robust Low-Frequency Variant Identification for Liquid Biopsy with a SLIMamp-Based NGS Chemistry Without Molecular Barcoding (Poster Number: ST145)
    Robust Bioinformatic Method for Estimating Tumor Content in cfDNA Using Denoised Target Sequencing (Poster Number: I031)
    Pillar Biosciences oncoReveal methylQuant Panels: Accurate and Easy-to-Use Methylation NGS Assays Leveraging SLIMamp Technology (Poster Number: ST031)
    oncoReveal Fusion LBx: Single-Tube Multiplexed PCR-Based NGS assay for Detection of Multiple Gene Fusions from Cell Free RNA (Poster Number: ST041)
    Robust Detection of Copy Number Amplifications Using Pillar's oncoReveal™ Core LBx Panel with Low Input from Liquid Biopsy Samples (Poster Number: I011)
    Poster and abstract summaries of this research will be available onsite at Pillar Biosciences' booth #619.

Enhancing Scientific Discovery: Laboratory Automation's 9.6% CAGR Poised for Remarkable Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 28, 2023
Biotechnology, Technology, Health, Pharmaceutical, Other Science, Research, Software, Artificial Intelligence, Genetics, Science, Electronic Design Automation, Finnish Cultural and Academic Institutes, Drug discovery, Genomics, Abbott Laboratories, SE, Waters Corporation, Region, Automation, Good clinical laboratory practice, Maintenance, Danaher Corporation, Echo, Machine learning, Laboratory, Becton, Dickinson and Company headquarters, Laboratory information management system, Growth, Center for Urban and Regional Analysis, FDA, ChromeOS, BD, Beckman Coulter, SCIEX, Proteomics, LIMS, QIAGEN, Regenerative medicine, Molecular biology, Artificial intelligence, Love & Other Drugs, DXC, Medical device, Instrumentation, Manufacturing, Fine chemical

According to BIS Research, the laboratory automation market is segmented by product into liquid handling instruments, appliances, accessories, and software.

Key Points: 
  • According to BIS Research, the laboratory automation market is segmented by product into liquid handling instruments, appliances, accessories, and software.
  • The laboratory automation landscape is characterized by dynamic interactions among stakeholders, technologies, and trends that are shaping the industry's growth and innovation.
  • North America and Europe lead due to their advanced industries and substantial adoption of laboratory automation, while Asia-Pacific is poised for significant growth.
  • What is the growth potential of the global laboratory automation market in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World?

Synchron Completes Patient Enrollment for COMMAND Trial of Brain Computer Interface

Retrieved on: 
Tuesday, September 5, 2023
Technology, FDA, Health, Neurology, Other Science, Research, Physical Therapy, Medical Devices, Software, Health Technology, Hardware, Science, Data Management, Clinical Trials, University, SWITCH, BCI, BRAIN, FSIN, COMMAND, Clinical trial, Brain, Doctor of Philosophy, Paralysis, Blood, Motor cortex, FAHA, Patient, Journal of Neurology, Neurosurgery, and Psychiatry, Physician, Division, UPMC, IDE, Mount Sinai Health System, JAMA Neurology, NIH, Caregiver, Safety, Medical device, Engineering, Beckman Coulter, MD

Synchron , the endovascular brain-computer interface (BCI) company developing technology to restore functionality in patients with severe paralysis, today announced completion of patient enrollment in the US-based COMMAND trial.

Key Points: 
  • Synchron , the endovascular brain-computer interface (BCI) company developing technology to restore functionality in patients with severe paralysis, today announced completion of patient enrollment in the US-based COMMAND trial.
  • The early feasibility study assesses safety while evaluating quantified efficacy measures of the Synchron Switch™ motor neuroprosthesis in patients with severe paralysis.
  • The Synchron Switch brain computer interface is implanted in the blood vessel on the surface of the motor cortex of the brain via the jugular vein, through a minimally-invasive endovascular procedure.
  • Synchron published long-term safety results in JAMA Neurology from the SWITCH study that enrolled a total of four patients in Australia.

Automated Liquid Handling Industry Report 2023-2035: Patent Surge Reflects Thriving Innovation

Retrieved on: 
Wednesday, August 16, 2023
Society, Workflow, System, NGS, University, SLAS, Research, USD, HTC, Instrument, Data analysis, International Conference on Computer-Aided Design, Acquisition, Miniaturization, Laboratory, Investment, Asepsis, Robotics, Society for Laboratory Automation and Screening, Laboratory automation, Beckman Coulter, Conference, Picolit, Geography, Fine chemical, Modality

Since the guidelines for pharmaceutical liquid handling are constantly evolving, the need for liquid handling automation systems is also growing.

Key Points: 
  • Since the guidelines for pharmaceutical liquid handling are constantly evolving, the need for liquid handling automation systems is also growing.
  • Further, the ability of automated liquid handling systems to handle small amounts of liquid more efficiently and the growing demand for miniaturization are likely to be the key growth drivers in the automated liquid handling industry.
  • The automated liquid handling systems market is one of the most promising sectors within the healthcare industry.
  • Acquisitions, product distribution agreements and product commercialization agreements are the most common types of partnerships inked by stakeholders in the automated liquid handling systems industry.